Maria E. Ruiz-Rodriguez

Pamplona, NC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

Prognostic value of existing scoring systems for early mortality in phase I immunotherapy trials: a head-to-head real-world cohort study.

Prognostic value of existing scoring systems for early mortality in phase I immunotherapy trials: a head-to-head real-world cohort study.

Journal: Frontiers in oncology

Published: April 07, 2026

Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy.

Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: March 27, 2026

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal: Journal of hematology & oncology

Published: March 25, 2026

Feasibility and Safety of Autologous Dendritic Cell Vaccination Combined with Radio-Chemotherapy in Newly Diagnosed Glioblastoma: A Retrospective Single-Center Series.

Feasibility and Safety of Autologous Dendritic Cell Vaccination Combined with Radio-Chemotherapy in Newly Diagnosed Glioblastoma: A Retrospective Single-Center Series.

Journal: Vaccines

Published: December 10, 2025

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors.

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors.

Journal: ESMO open

Published: November 05, 2025

Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer.

Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer.

Journal: The Journal of clinical investigation

Published: October 07, 2025

Author Correction: Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.

Author Correction: Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.

Journal: Nature

Published: October 01, 2025

Fruquintinib saddles tumor immune tolerance by curbing pro-tumoral immature myeloid cell populations.

Fruquintinib saddles tumor immune tolerance by curbing pro-tumoral immature myeloid cell populations.

Journal: Frontiers in immunology

Published: September 05, 2025

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.

Journal: Neuro-oncology advances

Published: August 22, 2025

Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2- breast cancer via CX3CR1+ macrophages.

Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2- breast cancer via CX3CR1+ macrophages.

Journal: Nature cancer

Published: July 23, 2025

Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.

Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 05, 2025

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.

Journal: Cancer research communications

Published: January 02, 2025

Showing 1-12 of 93

Last Updated: 09/26/2026